Aptar Pharma’s PureHale® Technology Platform is the industry’s first portable, ready-to-use, nebulizer-like device that dispenses a continuous fine mist that targets the nasal cavity, throat and pharynx. When used in combination with saline or other natural ingredient formulations, PureHale® helps to prevent or relieve symptoms of upper respiratory tract conditions such as coughs and colds, allergies, dry nose or throat, and other irritations.
Knowing that fine mist particles are beneficial for moisturizing the upper airways, it was in Aptar Pharma’s interest to develop a deeper understanding of the therapeutic effects of PureHale® and to investigate the effective deposition in the mouth, nasal cavity and the throat.. As current analytical methods are not suitable for such studies, Aptar Pharma established a research cooperation with the University of Cyprus and their leading experts in Computational Fluid Particle Dynamics (CFPD).
In this webinar we will elaborate how PureHale®, an innovative Bag-on-Valve based technology, adds value to the treatment of upper respiratory conditions. We will introduce a new model that combines a Next Generation Impactor (NGI), and an altered setup of CFPD from the University of Cyprus that enables the assessment of deposition patterns of formulations in the upper airways.
Finally, we will present an outlook on the potential use of PureHale® for preventive treatments of upper respiratory tract conditions.
Key Learning Objectives
- Learn about a new application of Computational Fluid Particle Dynamics that simulates deposition in the upper respiratory tract
- Review PureHale® Technology- a portable nebulizer-like device
- Discover how PureHale® specifically targets the upper airways
- Explore the therapeutic outlook for PureHale®
